Pawar Rahul, Kasi Loknath Kumar Anup, Woodroof Janet, Cui Wei, McGuirk Joseph, Abhyankar Sunil, Ganguly Sid, Singh Anurag, Lin Tara, Aljitawi Omar
Department of Internal Medicine, University of Kansas Medical Center, Mailstop 2027, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Division of Hematology and Oncology, University of Kansas Medical Center, 2330 Shawnee Mission Parkway, Westwood, KS 66205, USA.
Case Rep Hematol. 2014;2014:743856. doi: 10.1155/2014/743856. Epub 2014 Dec 11.
Background. Allogeneic stem cell transplant is the treatment of choice for systemic cutaneous T-cell lymphoma (CTCL) which provides graft-versus-lymphoma effect. Herein we discuss a case of recurrence of CTCL skin lesions after cord blood transplant in a patient who continued to have 100% donor chimerism in bone marrow. Case Presentation. A 48-year-old female with history of mycosis fungoides (MF) presented with biopsy proven large cell transformation of MF. PET scan revealed multiple adenopathy in abdomen and chest suspicious for lymphoma and skin biopsy showed large cell transformation. She was treated with multiple cycles of chemotherapy. Posttherapy PET scan showed resolution of lymphadenopathy. Later she underwent ablative preparative regimen followed by single cord blood transplant. Bone marrow chimerism studies at day +60 after transplant showed 100% donor cells without presence of lymphoma. However 5 months after transplant she had recurrence of MF with the same genotype as prior skin lesion. Bone marrow chimerism study continued to show 100% donor cells. Conclusion. A differential graft-versus-lymphoma effect in our case prevented lymphoma recurrence systemically but failed to do so in skin. We hypothesize that this response may be due to presence of other factors in the bone marrow and lymph node microenvironments preventing recurrence in these sites.
背景。异基因干细胞移植是系统性皮肤T细胞淋巴瘤(CTCL)的首选治疗方法,可产生移植物抗淋巴瘤效应。在此,我们讨论一例脐带血移植后CTCL皮肤病变复发的病例,该患者骨髓中供体嵌合体持续为100%。病例报告。一名48岁有蕈样肉芽肿(MF)病史的女性,活检证实为MF大细胞转化。PET扫描显示腹部和胸部有多个肿大淋巴结,怀疑为淋巴瘤,皮肤活检显示大细胞转化。她接受了多个周期的化疗。化疗后PET扫描显示淋巴结病消退。后来她接受了清髓预处理方案,随后进行了单份脐带血移植。移植后第60天的骨髓嵌合体研究显示100%为供体细胞,且无淋巴瘤。然而,移植后5个月,她出现了与先前皮肤病变相同基因型的MF复发。骨髓嵌合体研究继续显示100%为供体细胞。结论。在我们的病例中,移植物抗淋巴瘤效应的差异系统性地预防了淋巴瘤复发,但在皮肤中未能做到。我们推测这种反应可能是由于骨髓和淋巴结微环境中存在其他因素,阻止了这些部位的复发。